ClinicalTrials.gg
RecruitingNCT07938489VIT-D-PNEUMONIUpdated Nov 16, 2026

Effect of Single High-Dose Vitamin D3 Versus Placebo on Hospital Length of Stay in Children With Severe Pneumonia.

An interventional study of Vitamin D3 Group and Placebo (Peanut Oil Solution) in Severe Pneumonia in Children, sponsored by Shaheed Mohtarma Benazir Bhutto Institue of Trauma. Recruiting at 1 site in Pakistan. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shaheed Mohtarma Benazir Bhutto Institue of Trauma · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
1 Year to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Pneumonia with a site in Pakistan — 10 open to participants now, 10 under way, 1 of them phase 3. Pneumonia · Pakistan.

Planned enrollment
13th of 31
114 · median 90
Started
2026
with 2 others
No phase
24 of 37
7 open now
Registered
37th of 37
by date

Among the 37 studies in Pneumonia with a site in Pakistan, this one is the 13th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2026, is one of 24 with no phase, and was the 37th registered.

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

10 of the 37 studies in Pneumonia with a site in Pakistan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.

This study: 1 Year to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Pneumonia with a site in Pakistan, or all of them as a file.
02

Study summary

Severe pneumonia is a major cause of morbidity and mortality among children and often requires hospitalization and prolonged medical care. Vitamin D plays an important role in immune regulation and inflammatory responses, and its supplementation may help improve outcomes in respiratory infections. However, evidence regarding its effectiveness in reducing the duration of hospital stay among children with severe pneumonia remains limited.

This randomized controlled trial will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children of either sex, aged 1-16 years, presenting with severe pneumonia will be enrolled through non-probability consecutive sampling. Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded.

Eligible participants will be randomly allocated into two groups using sealed opaque envelopes. Group A will receive a single oral dose of 200,000 IU vitamin D3 dissolved in 10 mL of peanut oil, while Group B will receive 10 mL of peanut oil as placebo. Both preparations will be identical in color, taste, smell, consistency, and container. Participants will be followed until discharge. Hospital length of stay, defined as the period from admission to discharge, will be recorded for each patient. Data will be analyzed using SPSS version 20. Mean hospital length of stay will be compared between the two groups using an independent samples t-test, with p≤0.05 considered statistically significant.

The study aims to determine whether a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia.

Read the detailed description

Pneumonia remains one of the leading causes of morbidity and mortality among children, particularly those under five years of age. Severe pneumonia frequently requires hospitalization, prolonged medical care, and close monitoring. Several host, environmental, and infectious factors contribute to the development and severity of childhood pneumonia, including inadequate breastfeeding, low birth weight, malnutrition, exposure to indoor air pollution, overcrowding, and inadequate immunization. Viral and bacterial infections may also occur simultaneously, contributing to disease severity and clinical complications.

Vitamin D has an important role in regulating immune function and inflammatory responses involved in host defense against infections. It is also considered important for normal lung development and preservation of respiratory function. Previous observational studies have suggested an association between vitamin D deficiency and increased susceptibility to respiratory tract infections. Furthermore, research has explored the potential protective effects of vitamin D supplementation against respiratory infections in children and adults.

Although vitamin D supplementation is a relatively simple and potentially inexpensive intervention, its effectiveness in improving clinical outcomes among children hospitalized with severe pneumonia remains uncertain. Previous studies evaluating vitamin D supplementation in children with pneumonia have reported inconsistent findings. Therefore, further clinical research is required to determine whether vitamin D supplementation can improve recovery and reduce the duration of hospitalization in children presenting with severe pneumonia.

This randomized controlled trial will compare the mean hospital length of stay among children with severe pneumonia receiving a single high dose of vitamin D3 and those receiving placebo. The study will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children will be enrolled, with 57 participants allocated to each group. The sample size has been calculated using OpenEpi software, with a 5% level of significance and 90% power. The mean hospital length of stay in the vitamin D supplementation group and placebo group, based on the pilot study, was 4.90 ± 0.37 days and 5.12 ± 0.46 days, respectively. Non-probability consecutive sampling will be used to enroll eligible participants.

Children of either sex, aged 1-16 years, presenting with severe pneumonia will be included in the study. Severe pneumonia will be identified in children presenting with cough and/or difficulty in breathing of less than three weeks' duration along with one or more of the following findings: respiratory rate of 60 or more breaths per minute in children younger than 2 months, 50 or more breaths per minute in children aged 2-11 months, or 40 or more breaths per minute in children aged 12 months or older; lower chest wall indrawing; increased work of breathing indicated by recessions, grunting, or nasal flaring; oxygen saturation (SpO2) of 92% or less; or a new pulmonary infiltrate on chest radiograph appearing as an opacity with or without an air bronchogram.

Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded from the study.

The study will be initiated after approval from the College of Physicians and Surgeons Pakistan and permission from the institutional ethical review committee. Written informed consent will be obtained from the parents or guardians of eligible children before enrollment. Demographic information, including age and gender, will be recorded for each participant. Eligible participants will be randomly allocated into two groups using sealed opaque envelopes bearing the labels A and B. Group A will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution, whereas Group B will receive 10 mL of peanut oil solution as placebo. Both preparations will be identical in color, taste, smell, consistency, and container.

All participants will be followed during their hospital stay. The duration of hospitalization will be recorded for each participant. Participants will be discharged when they demonstrate clinical improvement, stable vital signs, resolution of key danger signs, and the ability to tolerate oral medications. Hospital length of stay will be defined as the period from the date of hospital admission until the date of discharge and will be recorded in days for both groups.

Data will be collected using a structured proforma. In addition to demographic characteristics and assigned study group, information regarding family monthly income, maternal educational status, type of family (joint or nuclear), and type of residence (house or flat) will also be recorded. The primary outcome will be hospital length of stay, measured in days.

Data will be analyzed using Statistical Package for Social Sciences (SPSS), version 20. Mean and standard deviation will be calculated for quantitative variables, including age and hospital length of stay. The Kolmogorov-Smirnov test will be used to assess the distribution of quantitative variables. Normally distributed quantitative variables will be reported as mean ± standard deviation, whereas non-normally distributed variables will be presented as median and interquartile range. Frequencies and percentages will be calculated for qualitative variables, including gender, family monthly income, maternal educational status, type of family, and type of residence. The mean hospital length of stay will be compared between the two study groups using the independent samples t-test. Effect modifiers, including age, gender, family monthly income, maternal educational status, type of family, and type of residence, will be controlled through stratification. Post-stratification independent samples t-tests will be applied, with a p-value of 0.05 or less considered statistically significant.

The study aims to determine whether administration of a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia. The findings may provide evidence regarding the potential role of vitamin D3 supplementation as an adjunctive intervention in the management of severe childhood pneumonia.

03

Conditions studied

  • Severe Pneumonia in Children

Browse trials for

Keywords

  • Severe Pneumonia
  • Vitamin D3 Supplementation
  • Hospital Length of Stay
  • Cholecalciferol
  • Placebo
  • Children
04

Who can participate

Ages eligible
1 Year to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of either sex, between 1-16 years of age, presenting with severe pneumonia will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of tuberculosis.
  • Patients with history congenital heart disease and cleft lip/palate.
  • Patients with history of bronchial asthma.
  • Patients with upper airway abnormality.
  • Patients with history of UTI.
  • Patients with history of malaria, dengue and typhoid fever.
  • Patients with history of malnourishment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Vitamin D3 Group

    Participants allocated to this group will receive a single high oral dose of 200,000 IU vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

    Drug: Vitamin D3 Group

  • Placebo comparator
    Placebo Group

    Participants allocated to this group will receive 10 mL of peanut oil solution as placebo. The placebo preparation will be identical to the vitamin D3 solution in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

    Drug: Placebo (Peanut Oil Solution)

Interventions

  • DrugVitamin D3 Group

    Participants allocated to the vitamin D3 group will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

  • DrugPlacebo (Peanut Oil Solution)

    Participants allocated to the placebo group will receive 10 mL of peanut oil solution orally. The placebo preparation will be identical to the vitamin D3 preparation in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

06

What researchers measure

Primary outcomes

  1. Mean Hospital Length of Stay

    Hospital length of stay will be measured in days, from the date of hospital admission until the date of discharge. The mean hospital length of stay will be compared between children receiving a single high dose of vitamin D3 and those receiving placebo.

    Time frame: From hospital admission until discharge (3-14 days).

07

Study locations

1 of 1 sites recruiting
  • Department of Pediatircs, Mohtarma Benazir Bhutto Shaheed Hospital, Mirpur AJ&K
    Lahore, Punjab Province 61100, Pakistan
    Recruiting
08

References and documents

Publications

  • 9. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database Syst Rev 2018(7):23-33. 10. Singh N, Kamble D, Mahantshetti NS. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children. Indian J Pediatr. 2019;86(12):1105-11. 11. Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017 Dec;82(6):986-93. 12. Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, et al. Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. J Pediatr. 2017;187:323-7.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. No data-sharing plan has been established for this study. Study data will be used solely for the purposes of the approved research.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Of 259 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 4 months is below that.

Counting every sponsor, half of 266 studies reached it within 21 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938489
Lead sponsor
Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Responsible party
Adeel Bashir (Principal Investigator, Shaheed Mohtarma Benazir Bhutto Institue of Trauma) — Principal investigator
First posted
Nov 16, 2026
Start date
Jul 1, 2026
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Adeel Bashir Dr., MBBS, FCPS PGR
Contact
adeelbashir775@gmail.com
+92-311-5414375 ext. +92-311-541437

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion